Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17100705 | 0.80 | ALDH1A1 (0.49) | SMN1; SMN2POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL17100694 | 0.80 | TSHR (0.40) | SMN1; SMN2POLBKDM4EMEN1KMT2A | |
| SCHEMBL17100657 | 0.78 | MEN1 (0.46) | SMN1; SMN2POLBKDM4EMEN1KMT2A | |
| SCHEMBL17100587 | 0.76 | POLB (0.38) | SMN1; SMN2POLBMEN1KMT2AALDH1A1 | |
| SCHEMBL17115061 | 0.74 | ALOX5AP (0.52) | ALDH1A1MAPTTHRB | |
| SCHEMBL17100700 | 0.69 | TSHR (0.43) | SMN1; SMN2POLBKDM4EMEN1KMT2A | |
| SCHEMBL17100675 | 0.68 | ALDH1A1 (0.55) | SMN1; SMN2POLBKDM4EKMT2AALDH1A1 | |
| SCHEMBL17100752 | 0.68 | TSHR (0.44) | SMN1; SMN2KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL17100628 | 0.67 | TDP1 (0.52) | SMN1; SMN2POLBKDM4EMEN1KMT2A | |
| SCHEMBL17100701 | 0.66 | KMT2A (0.53) | SMN1; SMN2POLBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | REMYND NV (BE) | 2017-03-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073319-A1 | OXADIAZOLE COMPOUNDS | OXA1L, PSEN1, MAPT | SMN1; SMN2 11/4885POLB 2985/4885KDM4E 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.